Monoclonal Antibody Infliximab Biosimilar from Germany
Monoclonal antibody infliximab biosimilar is a biotechnologically produced chimeric antibody targeting TNF-alpha, used to treat inflammatory conditions like Crohn's disease. It is produced by recombinant DNA technology and is a therapeutic biological product. This product falls under tariff item 3002.12.00 as an immunological product, per Chapter 30 note 2.
Duty Rate — Germany → Canada
0%
Import Tips
• Provide evidence of the product's biosimilar status and Health Canada approval
• Ensure the product is not classified as a diagnostic reagent, which would be excluded from Chapter 30
• Verify that the product is not put up in measured doses for retail sale, which could shift classification to heading 30.04